Cover Image
市場調查報告書

腎盂腎炎:開發中產品分析

Pyelonephritis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 251523
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
腎盂腎炎:開發中產品分析 Pyelonephritis - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 69 Pages
簡介

所謂腎盂腎炎是特殊的一種泌尿道感染(UTI),通常從尿道和膀胱發病再轉到腎臟。主要的症狀·前兆有發熱和腹痛,頻繁的排尿,噁心嘔吐,意識混濁,背部痛·側腹部痛等。主要的致病因子包含了免疫系的弱化,及膀胱週邊神經的損傷等。主要的治療方法有抗生素等。

本報告提供全球各國的腎盂腎炎治療用的開發中產品的開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查結果。

目錄

簡介

  • 分析範圍

腎盂腎炎概要

治療藥的開發

  • 腎盂腎炎開發中產品:概要
  • 企業開發中的治療藥
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Achaogen Inc.
  • AstraZeneca Plc
  • Merck & Co., Inc.
  • MerLion Pharmaceuticals Pte Ltd
  • The Medicines Company
  • Zavante Therapeutics Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9680IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis - Pipeline Review, H2 2017, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape.

Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion and back pain or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract and damage to nerves around the bladder. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pyelonephritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pyelonephritis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 5, 2 and 1 respectively.

Pyelonephritis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pyelonephritis - Overview
    • Pyelonephritis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Pyelonephritis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pyelonephritis - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • AstraZeneca Plc
    • Meiji Seika Pharma Co Ltd
    • Merck & Co Inc
    • MerLion Pharmaceuticals Pte Ltd
    • The Medicines Company
    • Zavante Therapeutics Inc
  • Pyelonephritis - Drug Profiles
    • (avibactam + ceftazidime) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (ceftolozane sulfate + tazobactam sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (meropenem + vaborbactam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AAI-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • finafloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosfomycin tromethamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nacubactam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pyelonephritis - Dormant Projects
  • Pyelonephritis - Discontinued Products
  • Pyelonephritis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 05, 2017: Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting
      • Apr 17, 2017: The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam
      • Jan 30, 2017: FDA Approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections, Including Pyelonephritis
      • Oct 26, 2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2016
      • Oct 11, 2016: FDA Accepts Supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam)
      • Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
      • Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2016
      • Jun 02, 2016: Achaogen Awarded $20 Million Contract Option by BARDA to Support Development of Plazomicin for Multi-Drug Resistant Gram-Negative Infections
      • Jun 02, 2016: Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin
      • Apr 07, 2016: Merck To Present Data on ZERBAXA at ECCMID 2016
      • Feb 22, 2016: New Antibiotic Against Drug-Resistant Bacteria Now Available
      • Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections
      • Feb 25, 2015: Actavis Receives U.S. FDA Approval for AVYCAZ (CEFTAZIDIME-AVIBACTAM)
      • Jun 18, 2014: MerLion completes recruitment in Finafloxacin phase II cUTI trial
      • Aug 22, 2013: FDA Grants Qualified Infectious Disease Product Designation and Fast Track Status for MerLion Pharma's Lead Antibacterial Candidate Finafloxacin
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pyelonephritis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pyelonephritis - Pipeline by Achaogen Inc, H2 2017
  • Pyelonephritis - Pipeline by AstraZeneca Plc, H2 2017
  • Pyelonephritis - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
  • Pyelonephritis - Pipeline by Merck & Co Inc, H2 2017
  • Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017
  • Pyelonephritis - Pipeline by The Medicines Company, H2 2017
  • Pyelonephritis - Pipeline by Zavante Therapeutics Inc, H2 2017
  • Pyelonephritis - Dormant Projects, H2 2017
  • Pyelonephritis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Pyelonephritis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top